Astellas writes down another piece of its Audentes gene therapy acquisition
Astellas will take a $450 million (70 billion Japanese yen) hit in its latest quarter as it writes down the value of a preclinical gene …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
